---
title: "RTVA.US (RTVA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RTVA.US/news.md"
symbol: "RTVA.US"
name: "RTVA.US"
parent: "https://longbridge.com/en/quote/RTVA.US.md"
datetime: "2026-03-12T14:23:12.710Z"
locales:
  - [en](https://longbridge.com/en/quote/RTVA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RTVA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RTVA.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/RTVA.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/RTVA.US/news.md)


# RTVA.US (RTVA.US) — Related News

### [Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements](https://longbridge.com/en/news/278009200.md)
*2026-03-06T01:06:00.000Z*
> Rakovina Therapeutics Inc. has closed a $1 million private placement of convertible debenture units and entered into deb

### [Rakovina Therapeutics Upsizes Financing to Up to $2 Million](https://longbridge.com/en/news/276599869.md)
*2026-02-23T12:14:00.000Z*
> Rakovina Therapeutics has increased its financing to approximately $2 million from $1.5 million. The financing includes 

### [Rakovina Therapeutics boosts financing to $2.0M with $1.0M convertible debenture/warrant financing and $1.0M common share placement. Operations support.](https://longbridge.com/en/news/276498285.md)
*2026-02-21T00:52:07.000Z*
> A proposed financing plan includes a $1.0 million convertible debenture and warrant offering, along with a concurrent pr

### [04:00 ETNucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer](https://longbridge.com/en/news/276045179.md)
*2026-02-16T09:00:38.000Z*
> Nucleome Therapeutics has appointed Dr. Michelle Morrow as Chief Scientific Officer, effective February 23, 2026. Dr. Mo

### [Rakovina Therapeutics Reports Industry Validation and Interest in Novel ADC Payloads](https://longbridge.com/en/news/274784245.md)
*2026-02-04T09:00:13.000Z*